Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. 

In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while  managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities.

Guests: 

Dr Paula Rodríguez-Otero 

Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain  

Host: Isabel Olivera Martinez, PhD

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠